We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 613

PTAB Invalidates Multiple Claims of Patent for Treating Anemia with Iron Carbohydrate Complexes and Denies Motion to Amend Claims
  • Jones Day
  • USA
  • January 13 2017

On January 4, 2017, in a Final Written Decision in IPR2015-01490, the PTAB found 17 claims of a patent directed to methods of treating iron disorders


What Impact Will the New Trump Administration Have on State Attorney General Activity?
  • Jones Day
  • USA
  • January 10 2017

Some state Attorneys General are already expressing their intention to challenge the new Trump Administration ("Administration") as it moves to


PTAB Institutes IPR Proceedings Against Mayne Pharma’s Antifungal Formulation Patent
  • Jones Day
  • USA
  • January 6 2017

The PTAB instituted an IPR on claims of Mayne Pharma International Pty Ltd.’s (“Mayne”) U.S. Patent No. 6,881,745 B2 covering formulations of azole


Routine Trial-and-Error Approach to Protein Formulation Is Not Sufficient to Establish Obviousness Absent a Reasonable Expectation of Success in Achieving the Claimed Formulation
  • Jones Day
  • USA
  • January 5 2017

On December 22, 2016, in a final written decision in IPR2015-01537, the PTAB rejected an obviousness challenge brought by Momenta Pharmaceuticals, Inc


Food, Dietary Supplement & Cosmetics Regulatory Update Vol. III, Issue 16
  • Jones Day
  • USA
  • December 21 2016

FDA issued an interim final rule amending the regulation that governs when a food label may make a health claim on the relationship between dietary


Idenix Pharmaceuticals wins $2.54 billion infringement verdict
  • Jones Day
  • USA
  • December 21 2016

The global law firm Jones Day represented Idenix Pharmaceuticals, LLC (Idenix), a subsidiary of Merck & Co (NYSE: MRK), known as MSD outside the


Recent OIG Publications Address AKS Safe Harbors, CMP Regulations, and "Nominal Value" Policy
  • Jones Day
  • USA
  • December 16 2016

On December 6, 2016, the Office of Inspector General, U.S. Department of Health and Human Services ("HHS-OIG") released several publications


D.C. District Court Orders DHHS to Reduce Medicare Appeal Backlog Affecting Hundreds of Thousands of Appeals
  • Jones Day
  • USA
  • December 13 2016

Health care providers received a big win on December 5, 2016, when the U.S. District Court for the District of Columbia issued a decision granting


D.C. District Court Orders HHS to Reduce Medicare Appeal Backlog Affecting Hundreds of Thousands of Appeals
  • Jones Day
  • USA
  • December 13 2016

Health care providers received a big win on December 5, 2016, when the U.S. District Court for the District of Columbia issued a decision granting


When Relying upon Scientific Test Data in its Petition, the Petitioner Must Provide Sufficient Information to Permit the PTAB to Evaluate the Data and its Reliability
  • Jones Day
  • USA
  • December 6 2016

On November 14, 2016, the PTAB issued a Final Written Decision upholding Paragon Bioteck, Inc.’s patent, U.S. Patent No. 8,859,623 B1 (the “’623